Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

735
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
735
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

917
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
917
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Cancer Vaccines01:30

Cancer Vaccines

367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the Impacts of Preprocessing on the Metabolite Profile of Bitter Almond Using UPLC-MS/MS and GC-MS Analysis.

ACS omega·2026
Same author

Quasi-synchronization for complex networks with hybrid pinning intermittent control.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

Hierarchical endpoints and win statistics for geromedicine trials.

Nature aging·2026
Same author

Cell stress and death liberate the autophagy-inhibitory tissue stress hormone DBI/ACBP into the circulation.

Autophagy·2026
Same author

Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity.

Seminars in immunology·2026

Related Experiment Video

Updated: Jul 5, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K

BCL2 inhibition stimulates dendritic cell function for improved anticancer immunotherapy.

Peng Liu1,2, Liwei Zhao1,2, Guido Kroemer3,4,5

  • 1Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.

Genes and Immunity
|January 24, 2024
PubMed
Summary

Researchers identified BCL2 as a dendritic cell (DC) immune checkpoint. Inhibiting BCL2 enhances anti-cancer immunity, offering a new dual checkpoint blockade strategy for cancer immunotherapy.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.4K

Related Experiment Videos

Last Updated: Jul 5, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.4K

Area of Science:

  • Immunology
  • Cancer Biology
  • Genetics

Background:

  • Dendritic cells (DCs) are crucial for initiating anti-cancer immunity.
  • Identifying DC-specific immune checkpoints can enhance immunotherapy.
  • CRISPR/Cas9 screening offers a powerful tool for functional genomics.

Purpose of the Study:

  • To identify novel DC-specific immune checkpoints.
  • To evaluate the therapeutic potential of targeting these checkpoints in cancer.

Main Methods:

  • Developed a CRISPR/Cas9-based screening platform for DC genotype-phenotype analysis.
  • Performed whole-genome screening to identify gain-of-function phenotypes.
  • Investigated the role of BCL2 in DC function and anti-cancer immunity.
  • Assessed the efficacy of BCL2 inhibition alone and in combination with PD-1 blockade in mouse models.

Main Results:

  • Identified BCL2 as a DC-specific immune checkpoint.
  • BCL2 inhibition enhanced antigen presentation by conventional type-1 dendritic cells (cDC1).
  • Targeting BCL2 mediated T cell-dependent anti-cancer immunity.
  • Combined BCL2 inhibition (venetoclax) and PD-1 blockade synergistically increased anti-cancer efficacy in mice.

Conclusions:

  • BCL2 represents a novel DC-specific immune checkpoint.
  • Dual blockade of BCL2 and PD-1 offers a promising strategy for enhancing cancer immunotherapy.
  • Improving DC function and preventing T cell exhaustion can be combined for greater therapeutic benefit.